Eventide Asset Management LLC Has $61.70 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Eventide Asset Management LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 157.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 224,333 shares of the biopharmaceutical company’s stock after buying an additional 137,333 shares during the quarter. Eventide Asset Management LLC owned approximately 0.17% of Alnylam Pharmaceuticals worth $61,698,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $26,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $42,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $45,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In other news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 8,370 shares of company stock worth $2,100,703. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $253.74 on Friday. The stock has a fifty day moving average price of $271.48 and a 200-day moving average price of $240.29. The company has a market cap of $32.73 billion, a price-to-earnings ratio of -96.85 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period last year, the firm posted $1.15 EPS. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Piper Sandler reissued an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, Citigroup boosted their target price on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.